As part of its advocacy program in Europe, ACRO submits regulatory comments to European officials. This comment letter, submitted by ACRO to the European Medicines Agency (EMA) on April 29, 2026, regarding the EMA’s draft guidance on the conduct of clinical trials during public health emergencies can be found below.